UNITED THERAPEUTICS Corp (UTHR) stock
UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)
Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –
United Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
United Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $1.69B, up 22.9% year over year. For fiscal 2025 it was $1.56B, up 17.6% from the year before. Over ten years it grew 15.1% a year on average. The highest annual figure on record is $1.56B in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | +17.6% |
| FY2024 | Dec 31, 2024 | $1.33B | +35.7% |
| FY2023 | Dec 31, 2023 | $978.00M | +21.9% |
| FY2022 | Dec 31, 2022 | $802.50M | +34.2% |
| FY2021 | Dec 31, 2021 | $598.20M | -20.8% |
| FY2020 | Dec 31, 2020 | $755.70M | – |
| FY2019 | Dec 31, 2019 | -$206.60M | -126.5% |
| FY2018 | Dec 31, 2018 | $778.40M | +64.2% |
| FY2017 | Dec 31, 2017 | $474.20M | -26.3% |
| FY2016 | Dec 31, 2016 | $643.60M | +68.1% |
| FY2015 | Dec 31, 2015 | $382.80M | +7.7% |
| FY2014 | Dec 31, 2014 | $355.30M | -16.5% |
| FY2013 | Dec 31, 2013 | $425.27M | +31.4% |
| FY2012 | Dec 31, 2012 | $323.63M | +29.4% |
| FY2011 | Dec 31, 2011 | $250.20M | +18.3% |
| FY2010 | Dec 31, 2010 | $211.53M | +112.1% |
| FY2009 | Dec 31, 2009 | $99.72M | – |
| FY2008 | Dec 31, 2008 | -$40.43M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $313.60M | +63.6% |
| Q1 FY2026 | Mar 31, 2026 | $463.30M | +0.5% |
| Q4 FY2025 | Dec 31, 2025 | $346.20M | +1.5% |
| Q3 FY2025 | Sep 30, 2025 | $562.10M | +49.0% |
| Q2 FY2025 | Jun 30, 2025 | $191.70M | -17.4% |
| Q1 FY2025 | Mar 31, 2025 | $461.20M | +22.5% |
| Q4 FY2024 | Dec 31, 2024 | $341.20M | +126.4% |
| Q3 FY2024 | Sep 30, 2024 | $377.20M | +9.0% |
| Q2 FY2024 | Jun 30, 2024 | $232.20M | +118.4% |
| Q1 FY2024 | Mar 31, 2024 | $376.50M | +0.5% |
| Q4 FY2023 | Dec 31, 2023 | $150.70M | +17.6% |
| Q3 FY2023 | Sep 30, 2023 | $346.20M | +33.9% |
| Q2 FY2023 | Jun 30, 2023 | $106.30M | -16.3% |
| Q1 FY2023 | Mar 31, 2023 | $374.80M | +29.8% |
| Q4 FY2022 | Dec 31, 2022 | $128.20M | -26.6% |
| Q3 FY2022 | Sep 30, 2022 | $258.60M | +39.3% |
| Q2 FY2022 | Jun 30, 2022 | $127.00M | -14.3% |
| Q1 FY2022 | Mar 31, 2022 | $288.70M | +221.5% |
| Q4 FY2021 | Dec 31, 2021 | $174.60M | +38.4% |
| Q3 FY2021 | Sep 30, 2021 | $185.60M | -26.0% |
| Q2 FY2021 | Jun 30, 2021 | $148.20M | -9.6% |
| Q1 FY2021 | Mar 31, 2021 | $89.80M | -58.2% |
| Q4 FY2020 | Dec 31, 2020 | $126.20M | +23.1% |
| Q3 FY2020 | Sep 30, 2020 | $250.90M | +35.3% |
| Q2 FY2020 | Jun 30, 2020 | $164.00M | +23.4% |
| Q1 FY2020 | Mar 31, 2020 | $214.60M | – |
| Q4 FY2019 | Dec 31, 2019 | $102.50M | +20.0% |
| Q3 FY2019 | Sep 30, 2019 | $185.40M | -21.9% |
| Q2 FY2019 | Jun 30, 2019 | $132.90M | -26.1% |
| Q1 FY2019 | Mar 31, 2019 | -$627.40M | -327.6% |
| Q4 FY2018 | Dec 31, 2018 | $85.40M | – |
| Q3 FY2018 | Sep 30, 2018 | $237.50M | -8.1% |
| Q2 FY2018 | Jun 30, 2018 | $179.80M | +154.3% |
| Q1 FY2018 | Mar 31, 2018 | $275.70M | +19.5% |
| Q4 FY2017 | Dec 31, 2017 | -$85.80M | -152.5% |
| Q3 FY2017 | Sep 30, 2017 | $258.50M | +13.0% |
| Q2 FY2017 | Jun 30, 2017 | $70.70M | – |
| Q1 FY2017 | Mar 31, 2017 | $230.80M | – |
| Q4 FY2016 | Dec 31, 2016 | $163.40M | – |
| Q3 FY2016 | Sep 30, 2016 | $228.70M | – |
See a number that looks wrong?